Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Identifying the molecular mechanisms that promote optimal immune responses to coronavirus disease 2019 (COVID-19) vaccination is critical for future rational vaccine design. Here, we longitudinally profile innate and adaptive immune responses in 102 adults after the first, second, and third doses of mRNA or adenovirus-vectored COVID-19 vaccines. Using a multi-omics approach, we identify key differences in the immune responses induced by ChAdOx1-S and BNT162b2 that correlate with antigen-specific antibody and T cell responses or vaccine reactogenicity. Unexpectedly, we observe that vaccination with ChAdOx1-S, but not BNT162b2, induces an adenoviral vector-specific memory response after the first dose, which correlates with the expression of proteins with roles in thrombosis with potential implications for thrombosis with thrombocytopenia syndrome (TTS), a rare but serious adverse event linked to adenovirus-vectored vaccines. The COVID-19 Vaccine Immune Responses Study thus represents a major resource that can be used to understand the immunogenicity and reactogenicity of these COVID-19 vaccines.
[Display omitted]
•Multi-omics profiling of responses in 102 adults after COVID-19 vaccination•Baseline and innate responses correlate with vaccine immunogenicity/reactogenicity•ChAdOx1-S, but not BNT162b2, induces an adenoviral memory response after the first dose•ChAdOx1-S memory response correlates with expression of pro-thrombotic proteins
Ryan et al. use a multi-omics approach to longitudinally profile innate and adaptive immune responses in blood collected from 102 adults at baseline and post-vaccination with the ChAdOx1-S, BNT162b2, or mRNA-1273 vaccines. The study reveals key differences in immune responses to adenovirus-vectored compared with mRNA COVID-19 vaccines.